Competition law analysis of hospital-stem cell bank tie-up: no proven foreclosure, dominance, or broad turnover-based penalty.

A vertical agreement between a hospital and a stem cell bank was analysed under the Competition Act, 2002 for alleged foreclosure of the stem cell banking market. The material did not prove appreciable adverse effect on competition because the record did not support market foreclosure, the complainant evidence was weak, and the bank could still enroll patients through other hospitals, so liability under Section 3 was not established. Dominance was also not proved, as the relevant market definition was too narrow and unsupported by reliable evidence, so the abuse claim under Section 4 failed. Penalty could not be based on the hospital's entire turnover because any conduct, if at all, was limited to the relevant service segment.

---

---

Issues: (i) Whether the agreement between the hospital and the stem cell bank was an anti-competitive vertical restraint causing appreciable adverse effect on competition under the Act; (ii) whether the appellant was dominant in the relevant market and had abused that position; (iii) whether the penalty could be sustained on the basis of the appellant's entire turnover.

Issue (i): Whether the agreement between the hospital and the stem cell bank was an anti-competitive vertical restraint causing appreciable adverse effect on competition under the Act.

Analysis: The conclusion of contravention rested on the assumption that the impugned arrangement foreclosed the stem cell banking market. The record did not support that assumption. The complaint was substantially driven by a third party and the alleged affected patient was not examined. The agreement did not prevent the stem cell bank from enrolling patients through other hospitals, and the market contained multiple players. In the absence of proof that the arrangement restricted competition in the stem cell banking market or created entry barriers of a legally significant kind, the finding of contravention could not stand.

Conclusion: The agreement was not proved to be anti-competitive under Section 3 of the Competition Act, 2002.

Issue (ii): Whether the appellant was dominant in the relevant market and had abused that position.

Analysis: The finding of dominance was founded on an over-narrow market definition and on conjectural assumptions rather than reliable evidence. The material did not establish that the appellant had the requisite strength in the relevant market, and the Commission itself had reservations about the dominance analysis. Once dominance was not established, the allegation of abuse under Section 4 could not survive.

Conclusion: Dominance and abuse of dominant position were not established against the appellant.

Issue (iii): Whether the penalty could be sustained on the basis of the appellant's entire turnover.

Analysis: Penalty under the Act must bear a rational nexus to the contravention found. The appellant was a multi-speciality hospital and the impugned conduct, if at all, related only to stem cell banking in the context of maternity services. Clubbing the turnover of all hospital services was impermissible. In any event, once the substantive contravention failed, the penalty lacked foundation.

Conclusion: The penalty based on the appellant's total turnover was unsustainable.

Final Conclusion: The Commission's order could not be upheld, the information was liable to fail, and the appellant was entitled to complete relief.

Ratio Decidendi: A vertical agreement will attract liability under Sections 3 and 4 of the Competition Act, 2002 only when the relevant market, dominance, and anti-competitive effect are proved on reliable evidence, and any penalty must be confined to the turnover connected with the proven contravention.

---